Overview 
Everads is an emerging startup with novel delivery technology to treat retinal diseases via suprachoroidal administration and is developing an early-stage pipeline that leverages our technology. 

Our technology enables delivery of therapy to the choroid and retina via the suprachoroidal space (SCS), an emerging route of administration in ophthalmology due it its potential to increase drug efficacy and durability, thereby lowering patient burden. The potential benefits of SCS delivery are driving many pharmaceutical companies to explore this route, however, there are very few delivery technologies.

Everads’ technology offers an easy and safe injection of therapy to the back of the eye, overcoming some of the limitations of other SCS technologies with regards to particle size, volume, invasiveness and safety. Our technology has been validated in over 60 non-human-primates using various modalities including AAV vectors, anti-VEGF antibodies, nanoparticles, and other materials.

Everads was founded in 2017 within the RAD Biomed Accelerator in Tel Aviv. Its underlying technologies have been licensed from the Sheba Medical Center at Tel Hashomer.
 

 

​